Agreed, confirmation of the efficacy of MSC's is slowly building. There is:
Crohns disease (Alofisel which is approved in Europe/UK)
GVHD (approved in Japan and in the USA the ODAC voted 9:1 that it works for pediatric patients with steroid-refractory acute GVHD)
Chronic heart failure (MSB clinical trial found revascor provides a substantial and durable reduction in heart attacks, strokes and cardiac death)
As the list grows we should see more investors and money move into MSC/stem cell companies.
Cynata 6 month price target: $1.50 or just over a 200 million market cap based on new clinical trials starting and new partnerships.
CYP 2021 - The year ahead, page-106
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.005(1.72%) |
Mkt cap ! $52.99M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 30.5¢ | 29.0¢ | $42.83K | 145.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10526 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 54032 | 1 |
View Market Depth
| Last trade - 16.10pm 28/05/2024 (20 minute delay) ? |
|
|||||
|
Last
30.0¢ |
Change
0.005 ( 5.26 %) |
||||
| Open | High | Low | Volume | ||
| 29.0¢ | 30.0¢ | 29.0¢ | 33256 | ||
| Last updated 15.39pm 28/05/2024 ? | |||||
| CYP (ASX) Chart |